Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 6/20 | 0.45 |
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 3/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 2/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6001626 | 0.88 | MTNR1B (0.47) | MTNR1BDRD2CHRNA7HTR2CCNR1 | |
| SCHEMBL6405341 | 0.79 | MTNR1B (0.50) | MTNR1BDRD2 | |
| SCHEMBL6001636 | 0.79 | DRD2 (0.52) | MTNR1BDRD2HTR2CMEN1KMT2A | |
| SCHEMBL6002172 | 0.79 | OPRM1 (0.51) | MTNR1BHTR2CCNR1CNR2 | |
| SCHEMBL6406991 | 0.79 | MTNR1B (0.47) | MTNR1BDRD2CHRNA7CNR1CNR2 | |
| SCHEMBL6404018 | 0.78 | DRD2 (0.48) | MTNR1BDRD2CHRNA7HTR2C | |
| SCHEMBL6001623 | 0.77 | MTNR1B (0.70) | MTNR1BMTNR1A | |
| SCHEMBL6403192 | 0.77 | QDPR (0.47) | MTNR1BCHRNA7CNR1CNR2 | |
| SCHEMBL6409744 | 0.76 | DRD2 (0.57) | MTNR1BDRD2CHRNA7HTR2C | |
| SCHEMBL6404494 | 0.76 | DRD2 (0.57) | MTNR1BDRD2CHRNA7HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060166984-A1 | Amino substituted benzo(hetero)cyclic derivatives | BASF AKTIENGESELLSCHAFT (DE) | 2006-07-27 | — | — | US | disclosed |
| EP-1603395-A2 | AMINO SUBSTITUTED BENZO(HETERO)CYCLIC DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004080170-A2 | AMINO SUBSTITUTED BENZO(HETERO)CYCLIC DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166984-A1 | Amino substituted benzo(hetero)cyclic derivatives | CBR3, L3MBTL3, BRS3 | MTNR1B 1920/4885DRD2 1222/4885CHRNA7 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.